Elevated ETV4 expression in cholangiocarcinoma is linked to poor prognosis and may guide targeted therapies  

作　　者：Uchenna E Okpete Haewon Byeon 

机构地区：[1]Department of Digital Anti-Aging Healthcare(BK21),Inje University,Gimhae 50834,South Korea

出　　处：《World Journal of Gastrointestinal Oncology》2024年第11期4528-4531,共4页世界胃肠肿瘤学杂志（英文）

摘　　要：Cholangiocarcinoma(CCA),a highly aggressive bile duct cancer,is associated with late-stage diagnosis and limited treatment options,leading to poor patient outcomes.Early detection and personalized treatment strategies are crucial.The study by Wang et al highlights the prognostic potential of the PEA3 subfamily genes(ETV1,ETV4,and ETV5)in CCA,identifying ETV4 as a particularly promising biomarker.Their bioinformatic analysis revealed that elevated ETV4 expression correlates with poorer survival,positioning it as a strong indicator of disease progression.These findings suggest that ETV4 could enhance prognostic precision and guide personalized therapies,although further validation through large-scale clinical trials is essential.Challenges in clinical application include the need for comprehensive experimental validation and addressing the tumor heterogeneity in CCA.Future research should focus on validating these biomarkers in diverse cohorts and developing targeted therapies,especially in regions where CCA is endemic.

关 键 词：Prognostic biomarkers CHOLANGIOCARCINOMA Survival rates ETV4 expression PEA3 subfamily Precision medicine Targeted therapy 

分 类 号：R735.8[医药卫生—肿瘤]